|
1. Maximizing
Treatment Outcome in OCD
IRB# 5188
Principal
Investigator: Dr. H. Blair Simpson
To schedule a confidential screening, contact:
Jose Hernandez
#212-543-5367 or Dr. James Bender Jr. #212-543-5462
Overview of Study:
This study compares the effectiveness of two proven treatment
strategies for OCD patients who are currently on a serotonin reuptake
inhibitor (SRI, i.e., clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, or escitalopram)
but still have residual symptoms. Participants remain on their current
medication and receive either cognitive-behavioral therapy (CBT)
consisting of exposure and ritual prevention or an additional
medication (risperidone). The goal is to
compare these two augmentation strategies, each of which has been found
effective in prior studies. All treatment is at no charge. Note:
Patients who do not improve after 8.5 weeks of treatment will be
offered at no-cost the treatment they did not initially receive (either
the CBT or the add-on medication).
Click here to learn more about the study!
Key Eligibility Criteria:
18-70 years; both genders
Key Inclusion Criteria:
- OCD is the
primary problem
- On a stable dose
of a serotonin reuptake inhibitor
Key Exclusion Criteria:
- Medical or
psychiatric conditions that would make study participation
hazardous
- Patients who
have already had an adequate trial of these augmentation
strategies while on a serotonin reuptake inhibitor
Who is this study for?
OCD patients on medications who still have bothersome symptoms and
who have not previously received an adequate trial of these proven
augmentation strategies.
2. Imaging the Serotonin System in OCD
IRB#5494R
P.I. Dr. H. Blair Simpson
To schedule a
confidential screening, contact:
Jose Hernandez #212-543-5367 or Dr. James
Bender Jr. #212-543-5462
Overview of Study:
The study examines whether the brain serotonin system is different
in patients with obsessive-compulsive disorder (OCD) than in those
without OCD. One of the brain serotonin receptors will be measured
using a standard imaging procedure called positron emission tomography
(PET). An anatomical picture of the brain using magnetic resonance
imaging (MRI) is also done. Subjects are compensated $500 for their
participation and offered three months of OCD treatment at no cost to
them.
Eligibility:
18-55 years, both genders
Key Inclusion Criteria:
- OCD is the
primary problem.
- Not currently on
psychiatric medications.
Key Exclusion Criteria:
- Current medical
or neurological problem that would make participation hazardous
Who is this study for?
For people with OCD who are not on psychiatric medications and who
would like to help us answer the scientific question of whether their
brain differs in this way from people without OCD.
|
